In this pilot study, our goal was to enhance the predictive power of the abovementioned biomarkers by combining them into a MS disease activity (MSDA) score, either using a combination of six (RGC-32, IL-21, FasL, JNK1 p54, SIRT1, p-SIRT1) or four biomarkers (RGC-32, IL-21, FasL, JNK1 p54), in order to better detect relapses and response to GA therapy. This evidence concerns the gene IL21 and myeloid sarcoma.